Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, announced the publication of previously reported Phase III …
Read More